Related Experiment Video
Updated: Jun 10, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Immunotherapeutic polyoma and human papilloma virus-like particles
Torbjörn Ramqvist1, Tina Dalianis
1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, CCK R8:01, 171 76 Stockholm, Sweden.
Abstract:
Polyomavirus and human papillomavirus (HPV) virus-like particles (VLPs) can be obtained by producing their major capsid protein VP1 (for polyomavirus) or L1 (for HPV) free from other viral genes in, for example, a baculovirus insect system, yeast, Escherichia coli or similar systems. Polyomavirus and HPV VLPs can immunize healthy individuals, and in some cases T-cell-deficient hosts, against primary infection with the corresponding virus. Chimeric VLPs from polyomaviruses or HPVs containing fusion proteins between the VP1/L1 or VP2/VP3/L2 minor capsid proteins and selected antigens can also be produced. These VLPs can then induce B- or T-cell immune responses and be used as preventive or therapeutic vaccines against cancers induced by the corresponding virus, or a cancer bearing the selected tumor antigen.
Related Concept Videos
Poliomyelitis
Inhibitors of Virion Maturation and Assembly
Tumor Immunotherapy
Subviral Agents
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Cytomegalovirus Disease

